PDF(639 KB)
Significance of paroxysmal nocturnal hemoglobinuria clone in immunosuppressive therapy for children with severe aplastic anemia
LI Jun, ZONG Su-Yu, YIN Zi-Xi, GAO Yang-Yang, LIU Li-Peng, WAN Yang, LAN Yang, GONG Xiao-Wen, ZHU Xiao-Fan
Chinese Journal of Contemporary Pediatrics ›› 2022, Vol. 24 ›› Issue (3) : 303-308.
PDF(639 KB)
PDF(639 KB)
Significance of paroxysmal nocturnal hemoglobinuria clone in immunosuppressive therapy for children with severe aplastic anemia
Objective To study the association between paroxysmal nocturnal hemoglobinuria (PNH) clone and immunosuppressive therapy (IST) in children with severe aplastic anemia (SAA). Methods A retrospective analysis was performed on the medical data of 151 children with SAA who were admitted and received IST from January 2012 to May 2020. According to the status of PNH clone, these children were divided into a negative PNH clone group (n=135) and a positive PNH clone group (n=16). Propensity score matching was used to balance the confounding factors, and the impact of PNH clone on the therapeutic effect of IST was analyzed. Results The children with positive PNH clone accounted for 10.6% (16/151), and the median granulocyte clone size was 1.8%. The children with positive PNH clone had an older age and a higher reticulocyte count at diagnosis (P<0.05). After propensity score matching, there were no significant differences in baseline features between the negative PNH clone and positive PNH clone groups (P>0.05). The positive PNH clone group had a significantly lower overall response rate than the negative PNH clone group at 6, 12, and 24 months after IST (P<0.05). The evolution of PNH clone was heterogeneous after IST, and the children with PNH clone showed an increase in the 3-year cumulative incidence rate of aplastic anemia-PNH syndrome (P<0.05). Conclusions SAA children with positive PNH clone at diagnosis tend to have poor response to IST and are more likely to develop aplastic anemia-PNH syndrome.
Aplastic anemia / Paroxysmal nocturnal hemoglobinuria / Clonal evolution / Immunosuppressive therapy / Child
1 Luzzatto L, Risitano AM. Advances in understanding the pathogenesis of acquired aplastic anaemia[J]. Br J Haematol, 2018, 182(6): 758-776. PMID: 29974931. DOI: 10.1111/bjh.15443.
2 Yoshida N, Kojima S. Updated guidelines for the treatment of acquired aplastic anemia in children[J]. Curr Oncol Rep, 2018, 20(9): 67. PMID: 29961134. DOI: 10.1007/s11912-018-0716-8.
3 Narita A, Muramatsu H, Sekiya Y, et al. Paroxysmal nocturnal hemoglobinuria and telomere length predicts response to immunosuppressive therapy in pediatric aplastic anemia[J]. Haematologica, 2015, 100(12): 1546-1552. PMID: 26315930. PMCID: PMC4666330. DOI: 10.3324/haematol.2015.132530.
4 Gargiulo L, Zaimoku Y, Scappini B, et al. Glycosylphosphatidylinositol-specific T cells, IFN-γ-producing T cells, and pathogenesis of idiopathic aplastic anemia[J]. Blood, 2017, 129(3): 388-392. PMID: 27903525. DOI: 10.1182/blood-2016-09-740845.
5 Fattizzo B, Dunlop A, Ireland RM, et al. Prognostic and predictive impact of small PNH clones in a large cohort of patients with myelodysplastic syndromes and aplastic anemia: a single-center experience[J]. Blood, 2018, 132(Suppl_1): 3870. DOI: 10.1182/blood-2018-99-116772.
6 Kulagin A, Lisukov I, Ivanova M, et al. Prognostic value of paroxysmal nocturnal haemoglobinuria clone presence in aplastic anaemia patients treated with combined immunosuppression: results of two-centre prospective study[J]. Br J Haematol, 2014, 164(4): 546-554. PMID: 24261566. DOI: 10.1111/bjh.12661.
7 Najean Y, Haguenauer O. Long-term (5 to 20 years) evolution of nongrafted aplastic anemias. The Cooperative Group for the Study of Aplastic and Refractory Anemias[J]. Blood, 1990, 76(11): 2222-2228. PMID: 2257296. DOI: 10.1182/blood.V76.11.2222.2222.
8 Narita A, Muramatsu H, Okuno Y, et al. Development of clinical paroxysmal nocturnal haemoglobinuria in children with aplastic anaemia[J]. Br J Haematol, 2017, 178(6): 954-958. PMID: 28643364. DOI: 10.1111/bjh.14790.
9 中华医学会儿科学分会血液学组, 《中华儿科杂志》编辑委员会. 儿童获得性再生障碍性贫血诊疗建议[J]. 中华儿科杂志, 2014, 52(2): 103-106. DOI: 10.3760/cma.j.issn.0578-1310.2014.02.006.
10 Lian Y, Shi J, Nie N, et al. Evolution patterns of paroxysmal nocturnal hemoglobinuria clone and clinical implications in acquired bone marrow failure[J]. Exp Hematol, 2019, 77: 41-50. PMID: 31472171. DOI: 10.1016/j.exphem.2019.08.005.
11 de Latour RP, Mary JY, Salanoubat C, et al. Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategories[J]. Blood, 2008, 112(8): 3099-3106. PMID: 18535202. DOI: 10.1182/blood-2008-01-133918.
12 Ma XR, Wang J, Zhang WG, et al. Comparison of porcine anti-human lymphocyte globulin and rabbit anti-human thymocyte globulin in the treatment of severe aplastic anemia: a retrospective single-center study[J]. Eur J Haematol, 2016, 96(3): 260-268. PMID: 25966958. DOI: 10.1111/ejh.12584.
13 Camitta BM. What is the definition of cure for aplastic anemia?[J]. Acta Haematol, 2000, 103(1): 16-18. PMID: 10705154. DOI: 10.1159/000040999.
14 袁晓英, 王亚哲, 石韦华, 等. 流式检测PNH克隆的方法学探讨及临床筛检和意义[J]. 中国生物工程杂志, 2019, 39(9): 33-40. DOI: 10.13523/j.cb.20190905.
15 Tu JK, Pan H, Li RN, et al. PNH clones for aplastic anemia with immunosuppressive therapy: a systematic review and meta-analysis[J]. Acta Haematol, 2021, 144(1): 34-43. PMID: 32877903. DOI: 10.1159/000506387.
16 Wang B, He B, Zhu YD, et al. The predictive value of pre-treatment paroxysmal nocturnal hemoglobinuria clone on response to immunosuppressive therapy in patients with aplastic anemia: a meta-analysis[J]. Hematology, 2020, 25(1): 464-472. PMID: 33269994. DOI: 10.1080/16078454.2020.1848083.
17 Yoshida N, Yagasaki H, Takahashi Y, et al. Clinical impact of HLA-DR15, a minor population of paroxysmal nocturnal haemoglobinuria-type cells, and an aplastic anaemia-associated autoantibody in children with acquired aplastic anaemia[J]. Br J Haematol, 2008, 142(3): 427-435. PMID: 18537977. DOI: 10.1111/j.1365-2141.2008.07182.x.
18 Timeus F, Crescenzio N, Lorenzati A, et al. Paroxysmal nocturnal haemoglobinuria clones in children with acquired aplastic anaemia: a prospective single centre study[J]. Br J Haematol, 2010, 150(4): 483-485. PMID: 20456361. DOI: 10.1111/j.1365-2141.2010.08219.x.
19 Mon Père N, Lenaerts T, Pacheco JM, et al. Evolutionary dynamics of paroxysmal nocturnal hemoglobinuria[J]. PLoS Comput Biol, 2018, 14(6): e1006133. PMID: 29912864. PMCID: PMC6023248. DOI: 10.1371/journal.pcbi.1006133.
20 Dingli D, Luzzatto L, Pacheco JM. Neutral evolution in paroxysmal nocturnal hemoglobinuria[J]. Proc Natl Acad Sci U S A, 2008, 105(47): 18496-18500. PMID: 19011109. PMCID: PMC2587638. DOI: 10.1073/pnas.0802749105.
21 Scheinberg P, Marte M, Nunez O, et al. Paroxysmal nocturnal hemoglobinuria clones in severe aplastic anemia patients treated with horse anti-thymocyte globulin plus cyclosporine[J]. Haematologica, 2010, 95(7): 1075-1080. PMID: 20595102. PMCID: PMC2895030. DOI: 10.3324/haematol.2009.017889.
22 Bat T, Abdelhamid ON, Balasubramanian SK, et al. The evolution of paroxysmal nocturnal haemoglobinuria depends on intensity of immunosuppressive therapy[J]. Br J Haematol, 2018, 182(5): 730-733. PMID: 28804905. PMCID: PMC5812827. DOI: 10.1111/bjh.14862.
23 Yenerel MN, Muus P, Wilson A, et al. Clinical course and disease burden in patients with paroxysmal nocturnal hemoglobinuria by hemolytic status[J]. Blood Cells Mol Dis, 2017, 65: 29-34. PMID: 28437723. DOI: 10.1016/j.bcmd.2017.03.013.
24 Socié G, Schrezenmeier H, Muus P, et al. Changing prognosis in paroxysmal nocturnal haemoglobinuria disease subcategories: an analysis of the International PNH Registry[J]. Intern Med J, 2016, 46(9): 1044-1053. PMID: 27305361. DOI: 10.1111/imj.13160.
25 Lee JW, Peffault de Latour R, Brodsky RA, et al. Effectiveness of eculizumab in patients with paroxysmal nocturnal hemoglobinuria (PNH) with or without aplastic anemia in the International PNH Registry[J]. Am J Hematol, 2019, 94(1): E37-E41. PMID: 30370949. DOI: 10.1002/ajh.25334.
